References
- Christ JE, Lotze EC. 1975. The residual ovary syndrome. Obstetrics and Gynecology 45:551–556.
- Dekel A, Efrat Z, Orvieto R, Levy T, Dicker D, Gal R. 1996. The residual ovary syndrome: a 20-year experience. The European Journal of Obstetrics and Gynecology and Reproductive Biology 68:159–164.
- Fu SC, Su HY. 2018. Residual ovarian syndrome: a case report with classic symptoms, imaging and pathology findings, and treatment. Taiwanese Journal of Obstetrics and Gynecology 57:753–754.
- Maeda N, Izumiya C, Taniguchi K, Matsushima S, Mita S, Shimizu Y, et al. 2014. Dienogest improves human leucocyte antigen-DR underexpression and reduces tumour necrosis factor-αproduction in preritoneal fluid cells from women with endometriosis. The European Journal of Obstetrics and Gynecology and Reproductive Biology 177:48–51.
- Rapisarda AM, Cianci A, Caruso S, Vitale SG, Valenti G, Piombino E, et al. 2018. Benign multicystic mesothelioma and peritoneal inclusion cysts: Are they the same clinical and histopathological entities? A systematic review to find an evidence-based management. Archives of Gynecology and Obstetrics 297:1353–1375.
- Ruan X, Seeger H, Mueck AO. 2012. The pharmacology of dienogest. Maturitas 71:337–344.
- Tamai H, Kinugasa M, Nishio M, Miyake M. 2019. Peritoneal inclusion cysts treated with a levonorgestrel-releasing intrauterine system: a case report. Case Reports in Women's Health 22:1–3.
- Vallerie AM, Lerner JP, Wright JD, Baxi LV. 2009. Peritoneal inclusion cysts: a review. Obstetrical & Gynecological Survey 64:321–334.